Learn, Analyse & Invest
only with
only with
+91
Download Orca
Jyoti Structures Ltd.
Jyoti Structures
Jyoti Structures Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
Infrastructure
Small-cap - With a market cap of ₹10.77 Cr.
| EX-Date | Purpose |
|---|---|
| 14 04 2021 | Audited Results & A.G.M. Inter alia, to consider, approve and take on record the following matters: 1) Standalone Cash Flow statement for the Quarter and Half Year Ended September 30, 2019 2) Standalone Cash Flow statement for the Quarter and Financial Year Ended March 31, 2020 3) Consolidated Unaudited Financial Results together with its Limited Review Report for the Quarter Ended June 30, 2019 4) Consolidated Unaudited Financial Results together with Limited Review Report for the Quarter and Half Year Ended September 30, 2019 5) Consolidated Unaudited Financial Results together with Limited Review Report for the Quarter and Nine Months Ended December 31, 2019 6) Consolidated Audited Financial Results of the Company for the Quarter and Financial year Ended March 31, 2020 7) Appointment of Statutory Auditor for the Financial Year 2020-2021 8) Appointment of Secretarial Auditor for the Financial Year 2019-2020 9) Director Report for the Financial Year 2019-2020 10) Appointment of Scrutinizer for 45th Annual General Meeting of the Company 11) Fix Book Closure date for 45th Annual General Meeting of the Company 12) Fix Cut-off Date for 45th Annual General Meeting of the Company. , inter alia, to consider, approve and take on record the following matters: 1) Standalone Cash Flow statement for the Quarter and Half Year Ended September 30, 2019 2) Standalone Cash Flow statement for the Quarter and Financial Year Ended March 31, 2020 3) Consolidated Unaudited Financial Results together with its Limited Review Report for the Quarter Ended June 30, 2019 4) Consolidated Unaudited Financial Results together with Limited Review Report for the Quarter and Half Year Ended September 30, 2019 5) Consolidated Unaudited Financial Results together with Limited Review Report for the Quarter and Nine Months Ended December 31, 2019 6) Consolidated Audited Financial Results of the Company for the Quarter and Financial year Ended March 31, 2020 7) Appointment of Statutory Auditor for the Financial Year 2020-2021 8) Appointment of Secretarial Auditor for the Financial Year 2019-2020 9) Director Report for the Financial Year 2019-2020 10) Appointment of Scrutinizer for 45th Annual General Meeting of the Company 11) Fix Book Closure date for 45th Annual General Meeting of the Company 12) Fix Cut-off Date for 45th Annual General Meeting of the Company |
| 06 08 2021 | Audited Results & A.G.M. Inter alia to consider, approve and take on record the following matters: 1) Standalone & Consolidated UFR with its Limited Review Report for the Quarter Ended June 30, 2020 2) Standalone & Consolidated UFR together with Limited Review Report for the Quarter and Half Year Ended September 30, 2020 3) Standalone & Consolidated UFR together with Limited Review Report for the Quarter and Nine Months Ended December 31, 2020 4) Standalone & Consolidated Audited Financial Results of the Company for the Quarter and Financial Year Ended March 31, 2021 5) Appointment of Statutory Auditor for the financial year 2021-2022 6) Appointment of Secretarial Auditor for the financial year 2020-2021 7) Director Report for the financial year 2020-2021 8) Matters related to 46th Annual General Meeting 10) Any other matter with the permission of the Chairperson |
| 09 11 2021 | Inter alia, to discuss and consider the issuances of various securities of the Company in terms of the implementation of the Approved Resolution Plan through Video Conferencing (MS Team). |
| 10 11 2021 | Quarterly Results |
| 18 01 2022 | Quarterly Results |
| 25 03 2022 | Quarterly Results & Increase in Authorised Capital Inter alia to consider, approve and take on record the following matters: 1) Increase the Authorized Share Capital of the Company. 3) Issue of Employee Stock Option Scheme (ESOS) of the Company. 4) Adoption of New Set of Articles of Association. 5) Borrowing Power limit of the Company under Section 180(1)(a) & 180(1)(c) of the Companies Act, 2013. 6) Notice for convening Extra Ordinary General Meeting. 7) Any other matter with the permission of the Chairperson. |
| 30 05 2022 | Audited Results & Quarterly Results |
| 12 08 2022 | Quarterly Results Inter alia, to consider the Appointment of M/s. G. P. Sharma & Co., LLP, Chartered Accountants (FRN 109957W/W100247) as the Statutory Auditor of the Company, for the term of five years |
| 06 09 2022 | Inter alia consider, approve and take on record the following matters: 1) Appointment of M/s. G. P. Sharma & Co., LLP, Chartered Accountants (FRN 109957W/W100247) as the Statutory Auditor of the Company, for a term of one year. 2) Appointment of Internal Auditor for the financial year 2022-2023 3) Director Report for the financial year 2021-2022 4) Calendar of events for 47th Annual General Meeting of the Company 5) Notice for convening 47th Annual General Meeting of the Company 6) Any other matter with the permission of the Chairperson |
| 11 11 2022 | Quarterly Results |
| 12 01 2023 | Inter alia, to consider and approve :- 1. Fund raising by way of issue of equity shares or any other instrument or security including fully/partly convertible debentures or by way of a composite issue of non-convertible debentures and warrants entitling the warrant holder(s) to apply for equity shares or any other eligible securities through qualified institutions placement, private placement/public issue of equity/debt securities, preferential issue or through any other permissible mode and/or combination thereof as may be considered appropriate, subject to such approvals as may be required including the approval of the members at a general meeting or through postal ballot and further subject to such other statutory/regulatory approvals, as applicable. 2. Any other matter with the permission of the Chairperson |
| 13 02 2023 | Quarterly Results |
| 12 05 2023 | Inter alia to consider, approve and take on record the following matters: 1. Allotment of 7,00,00,000 equity shares of the Company, pursuant to the conversion of 7,00,00,000 Compulsorily Convertible Preference Shares (CCPS) to Aion and Apollo Group. 2. Any other matter with the permission of the Chairperson |
| 29 05 2023 | Audited Results |
| 22 06 2023 | Inter alia consider, approve and take on record the following matters: 1) Appointment of M/s. G. P. Sharma & Co., LLP, Chartered Accountants (FRN 100957W/W100247) as the Statutory Auditor of the Company, for a term of one year. 2) Appointment of Internal Auditor for the financial year 2023-2024. 3) Appointment of Cost Auditor. 4) Reclassification of Authorized Share Capital and Consequent Amendment to memorandum. 5) Directors? Report for the financial year 2022-2023. 6) Calendar of events for 48 th Annual General Meeting of the Company. 7) Notice for convening 48 th Annual General Meeting of the Company. 8) Any other matter with the permission of the Chairperson. |
| 11 08 2023 | Quarterly Results |
| 25 09 2023 | Inter alia, to consider:- 1) Reclassification of Authorized Share Capital and Consequent Amendment to Memorandum 2) Resignation of Mr. Ramamirtham Kannan as Independent Director 3) Reconstitution of Stakeholder s Relationship Committee 4) Notice for convening Extra Ordinary General Meeting of the Company 5) Any other matter with the permission of the Chairperson. |
| 07 11 2023 | Preferential Issue of shares & Quarterly Results & Issue Of Warrants Inter-alia shall consider the proposal for raising of funds by issuance of equity shares / convertible bonds / debentures / warrants / preference shares / any other equity linked securities (?Securities?) by way of private placement, preferential issue or qualified institutions placement of Securities or any other method or mode as may be permitted under applicable laws, including the Companies Act, 2013 read with the rules notified thereunder and the Securities and Exchange Board of India (Issue of Capital and isclosure Requirements) Regulations, 2018, and to approve ancillary actions for the abovementioned fund raising subject to such regulatory / statutory approvals as may be required including approval of shareholders in this regard. |
| 16 11 2023 | Preferential Issue of shares & Rights Issue & Issue Of Warrants |
| 30 11 2023 | Rights Issue Inter alia, the proposal of fund raising by way of equity shares or other securities through rights issue as may be permitted under applicable law, subject to such regulatory/statutory approvals as may be required and other related matters |
| 13 02 2024 | Quarterly Results |
| 20 03 2024 | Inter alia, to consider various matters in connection with the Rights Issue, including the specific term of the Rights Issue, such as the determination of the Rights Issue price, rights entitlement ratio. |
| 06 11 2024 | Quarterly Results |
| 22 11 2024 | Rights Issue & Inter alia, to consider and transact the following businesses: (1) fund raising by way of equity shares or other securities through rights issue as may be permitted under applicable law(s), subject to such regulatory/statutory approvals as may be required and other related matters. |
| 03 02 2025 | Quarterly Results |
| 25 04 2025 | Inter alia, to consider and approve:- 1.Allotment of Equity Shares under ESOS Scheme 2021. 2.Any other matter with the permission of Chairperson. |
| 28 05 2025 | Audited Results |
| 14 08 2025 | Quarterly Results & Inter alia to consider, approve and take on record the following matters: 1. Appointment of Branch Auditors. 2. Appointment/Re-appointment of Internal Auditors. 3. Appointment of Secretarial Auditor. 4. Directors Report for the financial year 2024-2025. 5. Allotment of Equity Shares under ESOS Scheme 2021. 6. Any other matter with the permission of the Chairperson. |
| 30 09 2025 | Inter alia, to consider and approve:- 1. To take on record and deliberate upon the Letter of Intent (LOI) received from Telexcell Trade PTE LTD, Singapore, for a proposed acquisition of up to 25% equity stake in Welcure Drugs & Pharmaceuticals Ltd. at an indicative price of Rs.20 per share (a substantial premium over the prevailing market price). 2. To initiate the process of comprehensive due diligence in respect of the proposed transaction, including legal, financial, and regulatory aspects. 3. To consider authorizing the Company s representatives to negotiate and finalize the terms of definitive agreements, in alignment with Welcure s long-term growth strategy and compliance with applicable regulatory frameworks. 4. To explore enabling mechanisms for shareholder approval through postal ballot / general meeting, in line with SEBI, RBI, FEMA, and stock exchange requirements. 5. To deliberate on future strategic growth opportunities in global pharmaceutical and chemical exports, leveraging Telexcell s global trade network. |
| 12 11 2025 | Quarterly Results |
| 23 01 2026 | Quarterly Results |
| 30 04 2026 | Audited Results |
| 04 08 2026 | Quarterly Results |